{"hands_on_practices": [{"introduction": "The battle between antibiotics and bacteria often comes down to a molecular race. Carbapenemase enzymes, like NDM-1, are highly effective at destroying carbapenem antibiotics. This practice delves into the heart of this interaction, using the principles of Michaelis-Menten kinetics to quantify and compare how efficiently NDM-1 inactivates two different carbapenems, imipenem and meropenem. By calculating the catalytic efficiency ($k_{\\text{cat}}/K_{M}$), you will gain a quantitative understanding of why some antibiotics are more vulnerable to specific resistance enzymes than others [@problem_id:4931943].", "problem": "A clinical pharmacology lab is characterizing hydrolysis of two carbapenem antibiotics, imipenem and meropenem, by New Delhi metallo-beta-lactamase 1 (NDM-1). The enzyme kinetics were measured under initial-rate conditions in buffered solution at $37\\,^\\circ\\text{C}$. The following parameters were obtained:\n\n- Imipenem: $k_{\\text{cat}} = 3.1\\ \\text{s}^{-1}$, $K_{M} = 180\\ \\mu\\text{M}$.\n- Meropenem: $k_{\\text{cat}} = 0.95\\ \\text{s}^{-1}$, $K_{M} = 420\\ \\mu\\text{M}$.\n\nStarting from the foundational framework of Michaelis–Menten enzymology and accepted definitions of $k_{\\text{cat}}$ and $K_{M}$, reason which carbapenem is more pharmacologically compromised by NDM-1 and quantitatively compare the relative catalytic efficiencies under substrate-limited conditions. Report your final result as the fold-difference in catalytic efficiency of imipenem relative to meropenem, expressed as a unitless number. Round your answer to $3$ significant figures.", "solution": "The analysis begins with the foundational principles of Michaelis-Menten enzyme kinetics. The initial reaction velocity, $V_0$, for an enzyme-catalyzed reaction is described as a function of the substrate concentration, $[S]$, by the equation:\n$$ V_0 = \\frac{V_{\\text{max}} [S]}{K_M + [S]} $$\nIn this expression, $V_{\\text{max}}$ is the maximum reaction rate achieved at saturating substrate concentrations, and $K_M$ is the Michaelis constant, representing the substrate concentration at which the reaction velocity is half of $V_{\\text{max}}$. The maximum velocity is directly proportional to the total enzyme concentration, $[E]_T$, and the catalytic constant, $k_{\\text{cat}}$, which is the turnover number (the number of substrate molecules converted to product per enzyme molecule per unit time). This relationship is given by:\n$$ V_{\\text{max}} = k_{\\text{cat}} [E]_T $$\nSubstituting this into the Michaelis-Menten equation provides a more comprehensive form:\n$$ V_0 = \\frac{k_{\\text{cat}} [E]_T [S]}{K_M + [S]} $$\nThe provided kinetic parameters, $k_{\\text{cat}}$ and $K_M$, are intrinsic properties of the enzyme-substrate interaction under the specified experimental conditions (buffered solution at $37\\,^\\circ\\text{C}$).\n\nThe problem requests a comparison under \"substrate-limited conditions.\" This condition is formally defined by the inequality $[S] \\ll K_M$. In this regime, the concentration of the substrate (the antibiotic) is significantly lower than the Michaelis constant. Consequently, the denominator of the rate equation simplifies, as $K_M + [S] \\approx K_M$. The rate equation reduces to:\n$$ V_0 \\approx \\frac{k_{\\text{cat}} [E]_T [S]}{K_M} = \\left(\\frac{k_{\\text{cat}}}{K_M}\\right) [E]_T [S] $$\nThis simplified equation is a second-order rate law, where the rate is proportional to both enzyme and substrate concentrations. The term $\\frac{k_{\\text{cat}}}{K_M}$ is the apparent second-order rate constant, known as the catalytic efficiency or specificity constant. This constant is the most relevant measure for comparing an enzyme's effectiveness on different substrates when substrate is the limiting factor, as is often the case in physiological or pharmacological contexts.\n\nA higher catalytic efficiency signifies that the enzyme (NDM-1) is more effective at hydrolyzing and thus inactivating the substrate (the carbapenem antibiotic). Therefore, the carbapenem associated with a higher $\\frac{k_{\\text{cat}}}{K_M}$ value is more readily destroyed by NDM-1 and is considered more \"pharmacologically compromised.\"\n\nWe are provided with the kinetic parameters for the two carbapenems:\n- Imipenem (I): $k_{\\text{cat, I}} = 3.1\\ \\text{s}^{-1}$ and $K_{M, I} = 180\\ \\mu\\text{M}$.\n- Meropenem (M): $k_{\\text{cat, M}} = 0.95\\ \\text{s}^{-1}$ and $K_{M, M} = 420\\ \\mu\\text{M}$.\n\nFirst, we calculate the catalytic efficiency for each substrate.\nFor imipenem:\n$$ \\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_I = \\frac{k_{\\text{cat, I}}}{K_{M, I}} = \\frac{3.1\\ \\text{s}^{-1}}{180\\ \\mu\\text{M}} \\approx 0.01722\\ \\text{s}^{-1}\\mu\\text{M}^{-1} $$\nFor meropenem:\n$$ \\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_M = \\frac{k_{\\text{cat, M}}}{K_{M, M}} = \\frac{0.95\\ \\text{s}^{-1}}{420\\ \\mu\\text{M}} \\approx 0.00226\\ \\text{s}^{-1}\\mu\\text{M}^{-1} $$\nComparing these values, we find that $0.01722 > 0.00226$. Thus, NDM-1 has a higher catalytic efficiency for imipenem than for meropenem, indicating that imipenem's therapeutic efficacy is more severely compromised by this enzyme.\n\nThe problem requires a quantitative comparison, specifically the fold-difference in catalytic efficiency of imipenem relative to meropenem. This is calculated as the ratio of their respective specificity constants:\n$$ \\text{Fold-difference} = \\frac{\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_I}{\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_M} = \\frac{k_{\\text{cat, I}}}{K_{M, I}} \\cdot \\frac{K_{M, M}}{k_{\\text{cat, M}}} $$\nSubstituting the given values into this expression:\n$$ \\text{Fold-difference} = \\frac{(3.1\\ \\text{s}^{-1}) \\cdot (420\\ \\mu\\text{M})}{(0.95\\ \\text{s}^{-1}) \\cdot (180\\ \\mu\\text{M})} $$\nThe units $\\text{s}^{-1}$ and $\\mu\\text{M}$ cancel, yielding a dimensionless ratio as required.\n$$ \\text{Fold-difference} = \\frac{3.1 \\times 420}{0.95 \\times 180} = \\frac{1302}{171} \\approx 7.614035... $$\nThe problem requires rounding the final answer to $3$ significant figures. The calculated value is $7.61$. This result indicates that under substrate-limited conditions, NDM-1 hydrolyzes imipenem approximately $7.61$ times more efficiently than it hydrolyzes meropenem.", "answer": "$$\\boxed{7.61}$$", "id": "4931943"}, {"introduction": "Identifying antibiotic resistance quickly and accurately is critical in clinical settings. This exercise explores the biochemical foundation of the Carbapenemase Nordmann–Poirel (Carba NP) test, a method used to detect carbapenemase activity. You will apply principles of enzyme kinetics and acid-base chemistry to understand not only how the test works, but also to diagnose why it can produce false-negative results for important enzymes like OXA-48, highlighting the bridge between laboratory science and real-world diagnostic challenges [@problem_id:4932026].", "problem": "A clinical microbiology laboratory evaluates an Enterobacterales bloodstream isolate with reduced susceptibility to carbapenems. Minimum Inhibitory Concentrations (MICs) are as follows: ertapenem MIC $> 1\\,\\mu\\mathrm{g}/\\mathrm{mL}$, meropenem MIC $1\\,\\mu\\mathrm{g}/\\mathrm{mL}$, and imipenem MIC $1\\,\\mu\\mathrm{g}/\\mathrm{mL}$. The isolate tests negative in the Carbapenemase Nordmann–Poirel (Carba NP) test at $2$ hours. The laboratory suspects an OXA-$48$-like carbapenemase based on antibiogram patterns and epidemiology.\n\nUsing first principles from enzyme kinetics and acid–base chemistry, reason about the operating principle of the Carba NP test and why OXA-$48$-like enzymes may yield false negatives under standard testing times. Then, select the option that provides the most accurate mechanism explanation and an appropriate confirmatory molecular test.\n\nFoundational facts you may assume:\n- Beta-lactam hydrolysis opens the $\\beta$-lactam ring, generating acidic products that decrease $\\mathrm{pH}$, which can be monitored by a $\\mathrm{pH}$ indicator such as phenol red (red at $\\mathrm{pH}\\,\\approx 7.4$ to purple at $\\mathrm{pH}\\,> 8.2$, yellow at $\\mathrm{pH}\\,< 6.8$).\n- Under saturating substrate, the initial hydrolysis rate is approximately proportional to $k_{\\mathrm{cat}}[E]$ (from Michaelis–Menten kinetics, $v \\approx k_{\\mathrm{cat}}[E]$ when $[S] \\gg K_M$).\n- Class D serine $\\beta$-lactamases (e.g., OXA-$48$-like) and metallo-$\\beta$-lactamases differ in cofactor requirements; only the latter require zinc.\n\nWhich option best integrates the mechanism, the expected false-negative behavior with OXA-$48$-like enzymes, and a suitable confirmatory molecular approach?\n\nA. The Carba NP test detects carbapenemase activity by measuring acidification from imipenem hydrolysis via a $\\mathrm{pH}$ indicator. OXA-$48$-like enzymes often have low apparent $k_{\\mathrm{cat}}$ for imipenem and/or low expression, so over $2$ hours the cumulative $\\mathrm{H}^{+}$ generated may not drop the $\\mathrm{pH}$ below the indicator transition, yielding a false negative. Confirm by Polymerase Chain Reaction (PCR) targeting $bla_{\\text{OXA-48-like}}$ genes or a multiplex carbapenemase-gene PCR.\n\nB. The Carba NP test relies on chelating zinc with ethylenediaminetetraacetic acid (EDTA) to trigger a color change; OXA-$48$ enzymes are zinc-dependent, so without EDTA they are not detected. Confirm with an EDTA synergy disk test as the molecular gold standard.\n\nC. The Carba NP test measures outer membrane permeability changes as a proxy for carbapenemase activity; OXA-$48$ false negatives occur when porin loss predominates. Confirm by sequencing porin genes to establish carbapenemase presence.\n\nD. The Carba NP test uses nitrocefin cleavage monitored spectrophotometrically; OXA-$48$-like enzymes robustly cleave this substrate and therefore test positive reliably. Confirm by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) hydrolysis assay as the preferred molecular method.\n\nE. The Carba NP test tracks acidification from carbapenem hydrolysis, but OXA-$48$-like enzymes hyperproduce AmpC leading to false negatives. Confirm with an aztreonam–clavulanate synergy assay specific for OXA-$48$ detection at the molecular level.", "solution": "### Step 1: Extract Givens\n\n-   **Isolate**: An Enterobacterales bloodstream isolate.\n-   **Susceptibility Data (MICs)**:\n    -   Ertapenem MIC $> 1\\,\\mu\\mathrm{g}/\\mathrm{mL}$\n    -   Meropenem MIC $1\\,\\mu\\mathrm{g}/\\mathrm{mL}$\n    -   Imipenem MIC $1\\,\\mu\\mathrm{g}/\\mathrm{mL}$\n-   **Phenotypic Test Result**: Carbapenemase Nordmann–Poirel (Carba NP) test is negative at $2$ hours.\n-   **Clinical Suspicion**: OXA-$48$-like carbapenemase.\n-   **Foundational Fact 1**: $\\beta$-lactam hydrolysis opens the $\\beta$-lactam ring, generating acidic products that decrease $\\mathrm{pH}$. This is monitored by a $\\mathrm{pH}$ indicator, phenol red (red at $\\mathrm{pH}\\,\\approx 7.4$, yellow at $\\mathrm{pH}\\,< 6.8$).\n-   **Foundational Fact 2**: Under saturating substrate concentration ($[S] \\gg K_M$), the initial hydrolysis rate ($v$) is approximately $v \\approx k_{\\mathrm{cat}}[E]$, where $k_{\\mathrm{cat}}$ is the turnover number and $[E]$ is the enzyme concentration.\n-   **Foundational Fact 3**: Class D serine $\\beta$-lactamases (e.g., OXA-$48$-like) and metallo-$\\beta$-lactamases (MBLs) differ in cofactor requirements; only MBLs require zinc.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientific Grounding**: The problem is scientifically grounded. The scenario describes a common challenge in clinical microbiology: detecting carbapenemase-producing Enterobacterales (CPE). The provided MIC pattern, with elevated ertapenem resistance but borderline susceptibility to other carbapenems, is a classic presentation for OXA-$48$-like producers. The Carba NP test is a real-world assay, and its false-negative results for OXA-$48$-like enzymes are a well-documented phenomenon. The foundational facts about $\\beta$-lactam hydrolysis, Michaelis-Menten kinetics, and enzyme classification are correct and fundamental to the problem's context.\n-   **Well-Posedness**: The problem is well-posed. It asks for a mechanistic explanation for a specific observation (false-negative test) based on provided principles and then requires the selection of the best confirmatory strategy. This structure allows for a unique, logical solution.\n-   **Objectivity**: The problem is stated in precise, objective, and unbiased scientific language.\n-   **Completeness**: All necessary information to reason through the problem is provided in the givens and foundational facts. No critical information is missing.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and complete. I will now proceed to derive the solution.\n\n### Principle-Based Derivation and Solution\n\nThe Carba NP test is a phenotypic assay designed to detect carbapenemase activity directly from a bacterial lysate. Its operating principle relies on the chemical consequence of $\\beta$-lactam ring hydrolysis.\n\n$1$. **Mechanism of Detection**: As stated in Foundational Fact 1, the enzymatic cleavage of the amide bond in the $\\beta$-lactam ring of a carbapenem molecule (imipenem is the substrate in the standard Carba NP test) results in the formation of a carboxylate group.\n$$ \\text{Carbapenem (cyclic amide)} + \\mathrm{H_2O} \\xrightarrow{\\text{Carbapenemase}} \\text{Hydrolyzed Carbapenem (carboxylic acid)} $$\nThis reaction releases a proton ($\\mathrm{H}^{+}$) into the solution, causing a decrease in $\\mathrm{pH}$. The test medium is a weakly buffered solution containing the $\\mathrm{pH}$ indicator phenol red. A significant drop in $\\mathrm{pH}$ (e.g., from a starting $\\mathrm{pH}$ of $\\approx 7.4$ to below $6.8$) causes the indicator to change color from red to yellow, signaling a positive result.\n\n$2$. **Kinetics of the Reaction**: The rate of acid production is equal to the rate of carbapenem hydrolysis, $v$. According to Foundational Fact 2, under the substrate-saturating conditions of the test ($[S] \\gg K_M$), this rate is approximated by the maximal velocity, $V_{max}$.\n$$ v \\approx V_{max} = k_{\\mathrm{cat}}[E] $$\nHere, $k_{\\mathrm{cat}}$ is the catalytic turnover number (a measure of catalytic efficiency per enzyme molecule) for the specific carbapenem substrate, and $[E]$ is the concentration of the carbapenemase enzyme in the lysate. A color change within the specified time (e.g., $2$ hours) requires that the total amount of acid produced, which is the time integral of the rate, is sufficient to overcome the buffering capacity of the medium and lower the $\\mathrm{pH}$ past the indicator's transition point.\n\n$3$. **Explanation for OXA-$48$-like False Negatives**: The problem states the isolate tests negative at $2$ hours, despite suspicion of an OXA-$48$-like enzyme. OXA-$48$ and its variants are Class D serine $\\beta$-lactamases with hydrolytic activity against carbapenems. However, compared to other major carbapenemases like KPC (Class A) or NDM (Class B), they are kinetically weak hydrolyzers of carbapenems, especially imipenem. This means their $k_{\\mathrm{cat}}$ value for imipenem is relatively low. Consequently, even with a typical level of enzyme expression ($[E]$), the rate of hydrolysis ($v \\approx k_{\\mathrm{cat}}[E]$) is slow. A slow rate of hydrolysis leads to a slow rate of acid production. Over the standard incubation period of $2$ hours, the cumulative amount of $\\mathrm{H}^{+}$generated may be insufficient to lower the $\\mathrm{pH}$ below the threshold of phenol red. This leads to a lack of color change and a false-negative result. The test may turn positive if the incubation is prolonged (e.g., overnight), but this is outside the standard protocol.\n\n$4$. **Confirmatory Testing**: Given the potential for false negatives with phenotypic tests like the Carba NP for weak carbapenemases, a definitive diagnosis requires a genotypic method. A molecular test using Polymerase Chain Reaction (PCR) to detect the presence of the specific gene encoding the enzyme (e.g., $bla_{\\text{OXA-48-like}}$ genes) is the gold standard. Multiplex PCR assays are commonly used to screen for a panel of the most prevalent carbapenemase genes ($bla_{\\text{KPC}}$, $bla_{\\text{NDM}}$, $bla_{\\text{VIM}}$, $bla_{\\text{IMP}}$, $bla_{\\text{OXA-48-like}}$) simultaneously.\n\n### Option-by-Option Analysis\n\n**A. The Carba NP test detects carbapenemase activity by measuring acidification from imipenem hydrolysis via a $\\mathrm{pH}$ indicator. OXA-$48$-like enzymes often have low apparent $k_{\\mathrm{cat}}$ for imipenem and/or low expression, so over $2$ hours the cumulative $\\mathrm{H}^{+}$ generated may not drop the $\\mathrm{pH}$ below the indicator transition, yielding a false negative. Confirm by Polymerase Chain Reaction (PCR) targeting $bla_{\\text{OXA-48-like}}$ genes or a multiplex carbapenemase-gene PCR.**\n-   **Mechanism Explanation**: This correctly identifies the acidification from hydrolysis as the detection principle.\n-   **Reason for False Negative**: This provides the correct kinetic explanation—a low catalytic rate ($k_{\\mathrm{cat}}$) or low enzyme concentration ($[E]$) results in insufficient acid production within the $2$-hour window. This is the accepted scientific reason for this phenomenon.\n-   **Confirmatory Test**: This proposes the correct and gold-standard molecular method (PCR) for definitive identification.\n-   **Verdict**: **Correct**.\n\n**B. The Carba NP test relies on chelating zinc with ethylenediaminetetraacetic acid (EDTA) to trigger a color change; OXA-$48$ enzymes are zinc-dependent, so without EDTA they are not detected. Confirm with an EDTA synergy disk test as the molecular gold standard.**\n-   **Mechanism Explanation**: Incorrect. The Carba NP test measures hydrolysis directly, not inhibition by a chelator like EDTA. EDTA is used in tests to specifically identify zinc-dependent metallo-$\\beta$-lactamases (MBLs).\n-   **Reason for False Negative**: Incorrect. OXA-$48$ is a Class D serine $\\beta$-lactamase and is not zinc-dependent, as correctly stated in Foundational Fact 3.\n-   **Confirmatory Test**: Incorrect. An EDTA synergy disk test is a phenotypic, not molecular, test and is used for MBLs, not OXA-$48$.\n-   **Verdict**: **Incorrect**.\n\n**C. The Carba NP test measures outer membrane permeability changes as a proxy for carbapenemase activity; OXA-$48$ false negatives occur when porin loss predominates. Confirm by sequencing porin genes to establish carbapenemase presence.**\n-   **Mechanism Explanation**: Incorrect. The Carba NP test is performed on a cell lysate, which bypasses the outer membrane. It measures enzymatic activity, not membrane permeability.\n-   **Reason for False Negative**: Incorrect. Porin loss is a separate resistance mechanism that contributes to MIC values but does not cause a false negative in an enzymatic assay like Carba NP.\n-   **Confirmatory Test**: Incorrect. Sequencing porin genes investigates permeability defects, not the presence of a carbapenemase gene.\n-   **Verdict**: **Incorrect**.\n\n**D. The Carba NP test uses nitrocefin cleavage monitored spectrophotometrically; OXA-$48$-like enzymes robustly cleave this substrate and therefore test positive reliably. Confirm by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) hydrolysis assay as the preferred molecular method.**\n-   **Mechanism Explanation**: Incorrect. The Carba NP test uses a carbapenem (imipenem) and a $\\mathrm{pH}$ indicator, not the chromogenic cephalosporin nitrocefin. The choice of a carbapenem substrate is crucial for specificity.\n-   **Reason for False Negative**: This statement claims reliable *positive* results, contradicting the problem's premise of a false negative.\n-   **Confirmatory Test**: Incorrect classification. A MALDI-TOF hydrolysis assay is a powerful phenotypic method that measures mass changes due to hydrolysis, but it is not a molecular (genotypic) method.\n-   **Verdict**: **Incorrect**.\n\n**E. The Carba NP test tracks acidification from carbapenem hydrolysis, but OXA-$48$-like enzymes hyperproduce AmpC leading to false negatives. Confirm with an aztreonam–clavulanate synergy assay specific for OXA-$48$ detection at the molecular level.**\n-   **Mechanism Explanation**: The first clause is correct, but the reasoning is flawed. OXA-$48$ production is not causally linked to AmpC hyperproduction. They are distinct resistance mechanisms that can coexist but one does not cause the other, nor does AmpC hyperproduction explain the false negative in the Carba NP test for OXA-$48$.\n-   **Reason for False Negative**: Incorrect. The false negative is due to the intrinsic weak carbapenem-hydrolyzing activity of the OXA-$48$ enzyme itself, not interference from AmpC.\n-   **Confirmatory Test**: Incorrect. An aztreonam–clavulanate synergy assay does not exist for OXA-$48$ detection, and it is a phenotypic, not molecular, method. Aztreonam is stable to OXA-$48$ hydrolysis.\n-   **Verdict**: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4932026"}, {"introduction": "Effective antibiotic therapy requires maintaining drug concentrations above the level needed to kill bacteria. For time-dependent antibiotics like meropenem, continuous infusion is an advanced strategy to optimize this exposure. In this practical exercise, you will step into the role of a clinical pharmacist, using core pharmacokinetic principles to design a complete meropenem dosing regimen, including the calculation of a loading dose and a continuous infusion rate to achieve a specific therapeutic target in a patient [@problem_id:4931957].", "problem": "An adult patient with complicated Gram-negative sepsis is to receive the carbapenem antibiotic meropenem by continuous intravenous (IV) infusion. Assume linear, one-compartment pharmacokinetics with immediate distribution, 100% IV bioavailability, and constant parameters in this patient. The clinical pharmacodynamic goal is a steady-state (SS) free (unbound) plasma concentration of meropenem of $8\\,\\mathrm{mg/L}$. The meropenem plasma protein binding is low, with a fraction unbound $f_{u}=0.98$. The patient’s meropenem clearance is $\\mathrm{Cl}=12\\,\\mathrm{L/h}$. For an adult weighing $75\\,\\mathrm{kg}$, use a typical meropenem volume of distribution $V_{d}=0.30\\,\\mathrm{L/kg}$, assumed to reflect the apparent volume at steady state under the one-compartment model.\n\nStarting from fundamental definitions of clearance, steady state under constant-rate infusion, and the relationship between free and total concentrations, derive the infusion rate in $\\mathrm{mg/h}$ that will maintain the target free concentration at steady state. Then, compute the loading dose in $\\mathrm{mg}$ to be given as an IV bolus at the start of therapy to instantaneously achieve the target free concentration in plasma under the one-compartment assumption.\n\nExpress the infusion rate in $\\mathrm{mg/h}$ and the loading dose in $\\mathrm{mg}$. Round both final numeric results to four significant figures. Report your two numbers in the order: infusion rate, then loading dose. Do not include any units in your final reported values.", "solution": "The problem statement has been rigorously validated and found to be scientifically grounded, well-posed, and objective. It contains all necessary information and is free from contradictions or fallacies. We may therefore proceed with a formal solution.\n\nThe problem requires the calculation of two pharmacokinetic parameters for the antibiotic meropenem, administered as a continuous intravenous (IV) infusion: the infusion rate ($R_0$) required to maintain a target steady-state concentration, and the loading dose ($LD$) required to achieve this concentration instantaneously. The analysis will be based on a linear, one-compartment pharmacokinetic model.\n\nFirst, we calculate the infusion rate, $R_0$.\nThe fundamental principle of steady state ($ss$) for a drug administered by constant-rate infusion is that the rate of drug administration equals the rate of drug elimination from the body.\nThe rate of administration is the infusion rate, $R_0$.\nThe rate of elimination is the product of the total drug clearance ($\\mathrm{Cl}$) and the total plasma concentration at steady state ($C_{ss,total}$).\nTherefore, at steady state, we have the relationship:\n$$R_0 = \\mathrm{Cl} \\times C_{ss,total}$$\n\nThe problem provides a target for the free (unbound) plasma concentration at steady state, $C_{ss,free} = 8\\,\\mathrm{mg/L}$. The total concentration is related to the free concentration by the fraction unbound, $f_u$. The fraction unbound is defined as the ratio of the free drug concentration to the total drug concentration in plasma:\n$$f_u = \\frac{C_{free}}{C_{total}}$$\nThis relationship holds at any time, including at steady state:\n$$f_u = \\frac{C_{ss,free}}{C_{ss,total}}$$\nWe can rearrange this equation to express the total steady-state concentration in terms of the target free concentration and the fraction unbound:\n$$C_{ss,total} = \\frac{C_{ss,free}}{f_u}$$\nSubstituting this expression for $C_{ss,total}$ into our steady-state infusion rate equation gives the formula for $R_0$ based on the provided givens:\n$$R_0 = \\mathrm{Cl} \\times \\frac{C_{ss,free}}{f_u}$$\nThe given values are:\n- Clearance, $\\mathrm{Cl} = 12\\,\\mathrm{L/h}$\n- Target free steady-state concentration, $C_{ss,free} = 8\\,\\mathrm{mg/L}$\n- Fraction unbound, $f_u = 0.98$\n\nSubstituting these values into the derived equation for $R_0$:\n$$R_0 = (12\\,\\mathrm{L/h}) \\times \\frac{8\\,\\mathrm{mg/L}}{0.98}$$\n$$R_0 = \\frac{96}{0.98}\\,\\mathrm{mg/h} \\approx 97.95918\\,\\mathrm{mg/h}$$\nRounding to four significant figures as required, the infusion rate is:\n$$R_0 = 97.96\\,\\mathrm{mg/h}$$\n\nNext, we calculate the loading dose, $LD$.\nA loading dose is an initial, larger dose of a drug given to rapidly achieve the target therapeutic concentration. In a one-compartment model, the loading dose is the amount of drug needed to fill the apparent volume of distribution ($V_d$) to the desired total target concentration ($C_{target,total}$). The fundamental relationship is:\n$$LD = V_d \\times C_{target,total}$$\nThe target concentration for the loading dose is the total concentration that corresponds to the target free concentration, which is the same as the total steady-state concentration, $C_{ss,total}$.\n$$C_{target,total} = C_{ss,total} = \\frac{C_{ss,free}}{f_u} = \\frac{8\\,\\mathrm{mg/L}}{0.98}$$\nThe problem provides the specific volume of distribution, $V_{d,specific} = 0.30\\,\\mathrm{L/kg}$, and the patient's weight, $W = 75\\,\\mathrm{kg}$. The total volume of distribution for this patient is:\n$$V_d = V_{d,specific} \\times W = (0.30\\,\\mathrm{L/kg}) \\times (75\\,\\mathrm{kg}) = 22.5\\,\\mathrm{L}$$\nNow we can substitute the expressions for $V_d$ and $C_{target,total}$ into the loading dose equation:\n$$LD = (V_{d,specific} \\times W) \\times \\left(\\frac{C_{ss,free}}{f_u}\\right)$$\nSubstituting the numerical values:\n$$LD = (22.5\\,\\mathrm{L}) \\times \\left(\\frac{8\\,\\mathrm{mg/L}}{0.98}\\right)$$\n$$LD = \\frac{180}{0.98}\\,\\mathrm{mg} \\approx 183.67346\\,\\mathrm{mg}$$\nRounding to four significant figures as required, the loading dose is:\n$$LD = 183.7\\,\\mathrm{mg}$$\n\nThe required infusion rate is $97.96\\,\\mathrm{mg/h}$ and the loading dose is $183.7\\,\\mathrm{mg}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n97.96 & 183.7\n\\end{pmatrix}\n}\n$$", "id": "4931957"}]}